We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+13.86%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.41B
AUM Growth
+$274M
Cap. Flow
+$112M
Cap. Flow %
4.66%
Top 10 Hldgs %
24.57%
Holding
158
New
13
Increased
40
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$31.6M
2
TECX
Tectonic Therapeutic
TECX
+$27.9M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$22.5M
4
PANW icon
Palo Alto Networks
PANW
+$20.8M
5
SAGE
Sage Therapeutics
SAGE
+$18.8M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$52M
2
CAFD
8point3 Energy Partners LP
CAFD
+$18.9M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$18M
4
TWLO icon
Twilio
TWLO
+$12.5M
5
SNA icon
Snap-on
SNA
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 42.26%
2 Technology 16.99%
3 Consumer Discretionary 12.15%
4 Industrials 8.07%
5 Utilities 2.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPHI
51
DELISTED
INPHI CORPORATION
IPHI
$18.1M 0.75%
555,000
– –
STML
52
DELISTED
Stemline Therapeutics, Inc.
STML
$17.4M 0.72%
1,086,400
– –
AY
53
DELISTED
Atlantica Sustainable Infrastructure plc Ordinary Shares
AY
$17.4M 0.72%
864,000
+36,500
+4% +$725K
ANET icon
54
Arista Networks
ANET
$215B
$17M 0.71%
1,056,000
– –
MTD icon
55
Mettler-Toledo International
MTD
$27.9B
$16.8M 0.7%
+29,000
New +$16.5M
IMMU
56
DELISTED
Immunomedics Inc
IMMU
$16.5M 0.69%
+699,000
New +$14M
NBIX icon
57
Neurocrine Biosciences
NBIX
$18.7B
$15.3M 0.64%
156,000
– –
SNA icon
58
Snap-on
SNA
$21.2B
$15.2M 0.63%
94,470
-70,000
-43% -$10.6M
MYOK
59
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15M 0.62%
302,000
+150,000
+99% +$7.26M
AGIO icon
60
Agios Pharmaceuticals
AGIO
$1.95B
$15M 0.62%
178,000
– –
HASI icon
61
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.85B
$14.6M 0.61%
739,000
+15,000
+2% +$284K
SLDB icon
62
Solid Biosciences
SLDB
$836M
$14.3M 0.59%
26,667
– –
VMC icon
63
Vulcan Materials
VMC
$35.2B
$14.2M 0.59%
110,000
– –
CRUS icon
64
Cirrus Logic
CRUS
$6.65B
$14.2M 0.59%
370,000
– –
VYGR icon
65
Voyager Therapeutics
VYGR
$189M
$13.7M 0.57%
703,425
– –
MDGL icon
66
Madrigal Pharmaceuticals
MDGL
$11.4B
$12.9M 0.53%
46,000
+21,000
+84% +$3.69M
WVE icon
67
Wave Life Sciences
WVE
$1.11B
$12.5M 0.52%
326,400
-51,600
-14% -$2.22M
DOOR
68
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
$12.2M 0.51%
170,000
– –
BOLD
69
DELISTED
Audentes Therapeutics, Inc
BOLD
$10.5M 0.44%
275,000
+5,000
+2% +$185K
BHVN
70
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10M 0.42%
254,000
-92,000
-27% -$2.92M
BPMC
71
DELISTED
Blueprint Medicines
BPMC
$9.52M 0.4%
150,000
– –
PAYC icon
72
Paycom
PAYC
$7.53B
$9.49M 0.39%
96,000
– –
MNTA
73
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$9.08M 0.38%
444,000
+44,000
+11% +$944K
IFRX icon
74
InflaRx
IFRX
$253M
$8.87M 0.37%
275,000
– –
GWPH
75
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.86M 0.37%
63,500
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Eventide Asset Management held 158 positions worth $2.41B, up 13% from $2.14B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management deployed $112M of net new capital in Q2 2018, opening 13 new positions and adding to 40 existing holdings. Its largest new stake was Dianthus Therapeutics: 139,881 shares worth $29.5M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Snap-on, an estimated $10.6M trimmed.

  • Eventide Asset Management's largest Q2 2018 buy was Dianthus Therapeutics: 139,881 shares worth $29.5M.
  • Eventide Asset Management added most to Myovant Sciences Ltd. in Q2 2018, an estimated $22.5M increase.
  • Eventide Asset Management's biggest Q2 2018 reduction was Snap-on, cutting an estimated $10.6M.
  • Eventide Asset Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $52M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $2.41B portfolio in Q2 2018.
  • Eventide Asset Management opened 13 new positions and closed 14 in Q2 2018.
  • Eventide Asset Management's portfolio value rose 13% quarter-over-quarter to $2.41B.

Based on Eventide Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.